Covered recipient · General Payments record
MANISH JAIN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$232,778.36
361 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $144,450.00 | 73 |
| Consulting Fee | $30,331.25 | 9 |
| Honoraria | $27,087.00 | 14 |
| Travel and Lodging | $26,022.43 | 68 |
| Food and Beverage | $4,887.68 | 197 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $71,475.96 | 104 |
| Amgen Inc. | $51,671.36 | 64 |
| Lilly USA, LLC | $28,368.86 | 40 |
| Horizon Therapeutics plc | $25,168.42 | 33 |
| Aurinia Pharma U.S., Inc. | $15,366.69 | 16 |
| Novartis Pharmaceuticals Corporation | $14,886.22 | 33 |
| Janssen Scientific Affairs, LLC | $14,449.62 | 12 |
| GlaxoSmithKline, LLC. | $4,406.68 | 5 |
| AstraZeneca Pharmaceuticals LP | $2,862.18 | 5 |
| UCB, Inc. | $2,028.30 | 10 |
| PFIZER INC. | $1,480.00 | 1 |
| Janssen Biotech, Inc. | $348.28 | 25 |
| Exeltis, USA Inc. | $81.86 | 3 |
| Hikma Pharmaceuticals USA | $65.85 | 4 |
| Genentech USA, Inc. | $43.31 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $41.25 | 2 |
| Ultragenyx Pharmaceutical Inc. | $21.19 | 1 |
| HOSPIRA, INC. | $12.33 | 1 |
Page 3 of 8; records 101–150 of 361 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MANISH JAIN
NPI 1417075581 · CMS profile ID 109337
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
CHICAGO, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 8; records 101–150 of 361 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417075581?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MANISH JAIN, NPI 1417075581, CMS profile ID 109337. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 361 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417075581?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). MANISH JAIN, NPI 1417075581, CMS profile ID 109337. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 361 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417075581?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- MANISH JAIN, NPI 1417075581, CMS profile ID 109337, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 361 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1417075581?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
361 matching records · $232,778.36 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 361.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $20.53 | 10/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939295281 | CMS |
| ABBVIE INC. | $4,200.00 | 10/03/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892913003 | CMS |
| ABBVIE INC. | $394.40 | 09/30/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912995 | CMS |
| ABBVIE INC. | $248.40 | 09/30/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912999 | CMS |
| Janssen Biotech, Inc. | $11.40 | 09/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885851711 | CMS |
| ABBVIE INC. | $1,700.85 | 09/29/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912975 | CMS |
| ABBVIE INC. | $289.63 | 09/29/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912979 | CMS |
| ABBVIE INC. | $27.33 | 09/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912983 | CMS |
| ABBVIE INC. | $600.20 | 09/29/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912987 | CMS |
| ABBVIE INC. | $104.64 | 09/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912991 | CMS |
| Lilly USA, LLC | $1,450.00 | 09/29/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918137299 | CMS |
| Lilly USA, LLC | $2,300.00 | 09/29/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918174057 | CMS |
| ABBVIE INC. | $95.33 | 09/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912967 | CMS |
| ABBVIE INC. | $1,153.31 | 09/27/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912971 | CMS |
| ABBVIE INC. | $5.99 | 09/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912963 | CMS |
| Lilly USA, LLC | $517.80 | 09/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918160275 | CMS |
| Janssen Biotech, Inc. | $5.66 | 09/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885851811 | CMS |
| Exeltis, USA Inc. | $23.94 | 09/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947103507 | CMS |
| Lilly USA, LLC | $18.74 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918147263 | CMS |
| Amgen Inc. | $2,250.00 | 09/20/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939295317 | CMS |
| Hikma Pharmaceuticals USA | $20.87 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927074939 | CMS |
| UCB, Inc. | $8.42 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965172093 | CMS |
| Amgen Inc. | $657.76 | 09/19/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939881397 | CMS |
| UCB, Inc. | $19.53 | 09/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965171419 | CMS |
| ABBVIE INC. | $20.68 | 09/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912959 | CMS |
| Amgen Inc. | $12.16 | 09/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939295299 | CMS |
| Horizon Therapeutics plc | $2.15 | 09/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637767 | CMS |
| Horizon Therapeutics plc | $13.45 | 09/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637769 | CMS |
| Novartis Pharmaceuticals Corporation | $9.90 | 09/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893782787 | CMS |
| ABBVIE INC. | $1,800.00 | 09/12/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912955 | CMS |
| Janssen Scientific Affairs, LLC | $121.42 | 09/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887209052 | CMS |
| Lilly USA, LLC | $17.47 | 09/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918147261 | CMS |
| ABBVIE INC. | $17.69 | 09/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912951 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.08 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887364987 | CMS |
| Janssen Biotech, Inc. | $15.13 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885851805 | CMS |
| Janssen Biotech, Inc. | $2.11 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885851817 | CMS |
| Novartis Pharmaceuticals Corporation | $14.79 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893782783 | CMS |
| Amgen Inc. | $12.49 | 09/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933774333 | CMS |
| Janssen Scientific Affairs, LLC | $1,000.00 | 09/03/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887209028 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.10 | 09/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915177175 | CMS |
| Janssen Biotech, Inc. | $19.39 | 09/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885851705 | CMS |
| Amgen Inc. | $2,700.00 | 09/01/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939881367 | CMS |
| Amgen Inc. | $151.57 | 08/31/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939881371 | CMS |
| Novartis Pharmaceuticals Corporation | $10.74 | 08/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893782779 | CMS |
| ABBVIE INC. | $900.00 | 08/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912947 | CMS |
| Aurinia Pharma U.S., Inc. | $1,500.00 | 08/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954083021 | CMS |
| UCB, Inc. | $18.10 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908061963 | CMS |
| ABBVIE INC. | $7.25 | 08/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892912943 | CMS |
| Janssen Scientific Affairs, LLC | $3,500.00 | 08/27/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887209034 | CMS |
| Amgen Inc. | $2,250.00 | 08/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939881365 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $6,294,424.35 | 217 |
| PY2024 | Recipient | $81,964.76 | 5 |
| PY2024 | Principal investigator | $6,890,002.37 | 327 |
| PY2023 | Principal investigator | $5,216,246.96 | 447 |
| PY2022 | Principal investigator | $4,167,588.47 | 992 |
| PY2021 | Principal investigator | $10,218,382.27 | 105 |
| PY2020 | Recipient | $2,400.00 | 1 |
| PY2020 | Principal investigator | $1,737,256.74 | 58 |
| PY2019 | Recipient | $37,429.00 | 2 |
| PY2019 | Principal investigator | $113,567.82 | 39 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
217 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $636.18 | 12/29/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228811657 |
| Principal investigator 1 | PFIZER INC. | $800.15 | 12/29/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228811743 |
| Principal investigator 1 | PFIZER INC. | $262.77 | 12/29/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228811749 |
| Principal investigator 1 | PFIZER INC. | $20,790.00 | 12/25/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228815494 |
| Principal investigator 1 | Amgen Inc. | $23,500.00 | 12/24/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LLC | A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout | No dispute reported | 06/30/2026 | 1246641936 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297742 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297744 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297746 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297748 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297750 |
| Principal investigator 1 | Seqirus USA Inc | $788.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297754 |
| Principal investigator 1 | Seqirus USA Inc | $400.40 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297764 |
| Principal investigator 1 | Seqirus USA Inc | $400.40 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297766 |
| Principal investigator 1 | Seqirus USA Inc | $400.40 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297768 |
| Principal investigator 1 | Seqirus USA Inc | $400.40 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297770 |
| Principal investigator 1 | Seqirus USA Inc | $400.40 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297818 |
| Principal investigator 1 | Seqirus USA Inc | $788.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297820 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297824 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297828 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297834 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297836 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297838 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297840 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297842 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297844 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297846 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297848 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297850 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297852 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297854 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297856 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297858 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297860 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297862 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297864 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297866 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297868 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297870 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297872 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297874 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297876 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297878 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297880 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297882 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297884 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297886 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297888 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297890 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297892 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297894 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297896 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297898 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297900 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297902 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297904 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297906 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297908 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297910 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297912 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297914 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297916 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297918 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297920 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297922 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297924 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297926 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297928 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297930 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297932 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297934 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297936 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297938 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297940 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297942 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297944 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297946 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297948 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297950 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297952 |
| Principal investigator 1 | Seqirus USA Inc | $3,119.20 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297954 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297956 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297958 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297960 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297962 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297964 |
| Principal investigator 1 | Seqirus USA Inc | $1,064.00 | 12/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297966 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,000.00 | 12/12/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRAILS | A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C | No dispute reported | 06/30/2026 | 1185543630 |
| Principal investigator 1 | PFIZER INC. | $2,668.47 | 12/12/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228815532 |
| Principal investigator 1 | PFIZER INC. | $1,541.79 | 12/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228815592 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $66,632.80 | 12/03/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRAILS | A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA | No dispute reported | 06/30/2026 | 1185543622 |
| Principal investigator 1 | PFIZER INC. | $5,119.04 | 11/26/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228713376 |
| Principal investigator 1 | PFIZER INC. | $19,477.00 | 11/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228713966 |
| Principal investigator 1 | AstraZeneca UK Limited | $164,340.00 | 11/05/2025 | Non-covered Recipient Entity QUEST DIAGNOSTICS UNIVERSITY OF MIAMI | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity | No dispute reported | 06/30/2026 | 1185543620 |
| Principal investigator 1 | PFIZER INC. | $29,552.56 | 10/31/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228825084 |
| Principal investigator 1 | Seqirus USA Inc | $3,846.60 | 10/31/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810755 |
| Principal investigator 1 | Seqirus USA Inc | $1,057.05 | 10/31/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810760 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 10/27/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297826 |
| Principal investigator 1 | Seqirus USA Inc | $4,925.00 | 10/27/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297830 |
| Principal investigator 1 | Seqirus USA Inc | $11,000.00 | 10/27/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297832 |
| Principal investigator 1 | PFIZER INC. | $87,297.67 | 10/25/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228825401 |
| Principal investigator 1 | ARGENX US, INC. | $3,617.00 | 10/22/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150600 |
| Principal investigator 1 | ARGENX US, INC. | $2,178.00 | 10/22/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150604 |
| Principal investigator 1 | ARGENX US, INC. | $13,750.00 | 10/22/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150608 |
| Principal investigator 1 | ARGENX US, INC. | $2,500.00 | 10/15/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150595 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 10/15/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150613 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,978.34 | 10/08/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRAILS | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity | No dispute reported | 06/30/2026 | 1185543612 |
| Principal investigator 1 | PFIZER INC. | $4,044.60 | 10/08/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228818526 |
| Principal investigator 1 | Eli Lilly and Company | $2,450.00 | 09/29/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187882520 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $213,371.20 | 09/24/2025 | Non-covered Recipient Entity FLOURISH RESEARCH CHICAGO ANDERSONVILLE | A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA | No dispute reported | 06/30/2026 | 1185543614 |
| Principal investigator 1 | PFIZER INC. | $21,186.80 | 09/24/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228837277 |
| Principal investigator 1 | PFIZER INC. | $31,481.81 | 09/10/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228837270 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/10/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297814 |
| Principal investigator 1 | Seqirus USA Inc | $177.19 | 09/10/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297816 |
| Principal investigator 1 | Seqirus USA Inc | $789.00 | 09/10/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297822 |
| Principal investigator 1 | ARGENX US, INC. | $668.50 | 09/03/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150566 |
| Principal investigator 1 | ARGENX US, INC. | $103.50 | 09/03/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150572 |
| Principal investigator 1 | ARGENX US, INC. | $6.65 | 09/03/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150577 |
| Principal investigator 1 | ARGENX US, INC. | $35.80 | 09/03/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150582 |
| Principal investigator 1 | ARGENX US, INC. | $75.20 | 09/03/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150586 |
| Principal investigator 1 | ARGENX US, INC. | $159.00 | 09/03/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237150590 |
| Principal investigator 1 | PFIZER INC. | $4,044.60 | 09/03/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228837204 |
| Principal investigator 1 | PFIZER INC. | $51,741.20 | 08/28/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228841919 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 08/13/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297806 |
| Principal investigator 1 | Seqirus USA Inc | $1,500.00 | 08/13/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297808 |
| Principal investigator 1 | Seqirus USA Inc | $1,600.00 | 08/13/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297810 |
| Principal investigator 1 | PFIZER INC. | $2,073.60 | 08/08/2025 | Non-covered Recipient Entity Flourish Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228713788 |
| Principal investigator 1 | Amgen Inc. | $525.88 | 07/28/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246641927 |
| Principal investigator 1 | Eli Lilly and Company | $1,200.00 | 07/28/2025 | Non-covered Recipient Entity INTERSPOND LLC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187883578 |
| Principal investigator 1 | PFIZER INC. | $23,955.40 | 07/25/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228848664 |
| Principal investigator 1 | Seqirus USA Inc | $1,250.00 | 07/18/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297812 |
| Principal investigator 1 | PFIZER INC. | $54,481.00 | 07/16/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228848659 |
| Principal investigator 1 | PFIZER INC. | $1,377.14 | 07/08/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228713784 |
| Principal investigator 1 | PFIZER INC. | $533.91 | 07/08/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228713786 |
| Principal investigator 1 | PFIZER INC. | $455.47 | 07/08/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228713968 |
| Principal investigator 1 | PFIZER INC. | $533.91 | 07/08/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228713970 |
| Principal investigator 1 | PFIZER INC. | $28,448.00 | 06/27/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228850962 |
| Principal investigator 1 | PFIZER INC. | $69,328.40 | 06/14/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228851023 |
| Principal investigator 1 | PFIZER INC. | $1,200.00 | 06/14/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228851035 |
| Principal investigator 1 | PFIZER INC. | $2,101.17 | 05/21/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228855111 |
| Principal investigator 1 | PFIZER INC. | $8,448.30 | 05/14/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228855141 |
| Principal investigator 1 | PFIZER INC. | $5,118.84 | 05/07/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228855151 |
| Principal investigator 1 | PFIZER INC. | $3,620.00 | 05/06/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228855146 |
| Principal investigator 1 | PFIZER INC. | $2,400.38 | 05/02/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228855108 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,401.00 | 04/25/2025 | Non-covered Recipient Entity AVICENNA DM CLINICAL RESEARCH | A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C | No dispute reported | 06/30/2026 | 1185543618 |
| Principal investigator 1 | PFIZER INC. | $5,538.40 | 04/25/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228854578 |
| Principal investigator 1 | PFIZER INC. | $339,210.00 | 04/24/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228854501 |
| Principal investigator 1 | PFIZER INC. | $159.04 | 04/17/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228860478 |
| Principal investigator 1 | Eli Lilly and Company | $3.90 | 04/15/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187882242 |
| Principal investigator 1 | PFIZER INC. | $2,559.42 | 04/11/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228860488 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297774 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297778 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297780 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297782 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297784 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297786 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185297790 |
| Principal investigator 1 | Seqirus USA Inc | $1,186.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298034 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298036 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298040 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298042 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298044 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298046 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298048 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298050 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298052 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298054 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298056 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298058 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298060 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298062 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298064 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298066 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298068 |
| Principal investigator 1 | Seqirus USA Inc | $538.00 | 04/09/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298070 |
| Principal investigator 1 | Eli Lilly and Company | $16,400.00 | 04/07/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187883712 |
| Principal investigator 1 | PFIZER INC. | $73,399.00 | 03/27/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228861681 |
| Principal investigator 1 | Shionogi Inc | $3,800.00 | 03/19/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LL | A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults | No dispute reported | 06/30/2026 | 1250717545 |
| Principal investigator 1 | Shionogi Inc | $1,500.00 | 03/19/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LL | A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults | No dispute reported | 06/30/2026 | 1250717550 |
| Principal investigator 1 | Shionogi Inc | $1,500.00 | 03/19/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LL | A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults | No dispute reported | 06/30/2026 | 1250717565 |
| Principal investigator 1 | PFIZER INC. | $29,166.20 | 03/14/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228861749 |
| Principal investigator 1 | Eli Lilly and Company | $73.86 | 03/12/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187882592 |
| Principal investigator 1 | PFIZER INC. | $41,320.50 | 03/12/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228861660 |
| Principal investigator 1 | PFIZER INC. | $1,706.28 | 03/12/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228861701 |
| Principal investigator 1 | Shionogi Inc | $500.00 | 03/12/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LL | A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults | No dispute reported | 06/30/2026 | 1250717541 |
| Principal investigator 1 | Eli Lilly and Company | $794.04 | 03/10/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881888 |
| Principal investigator 1 | ModernaTX, Inc. | $2,246.00 | 03/05/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252968001 |
| Principal investigator 1 | ModernaTX, Inc. | $625.00 | 03/05/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252968003 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 03/05/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252968005 |
| Principal investigator 1 | PFIZER INC. | $4,265.70 | 03/05/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228861696 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,900.00 | 03/03/2025 | Non-covered Recipient Entity FLOURISH RESEARCH CHICAGO ANDERSONVILLE | A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine | No dispute reported | 06/30/2026 | 1185543626 |
| Principal investigator 1 | PFIZER INC. | $2,559.42 | 02/26/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228836587 |
| Principal investigator 1 | Eli Lilly and Company | $16,161.48 | 02/25/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187882816 |
| Principal investigator 1 | PFIZER INC. | $126.30 | 02/21/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228815280 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 02/20/2025 | Non-covered Recipient Entity INTERSPOND LLC | M19-944 - A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis | No dispute reported | 06/30/2026 | 1202453156 |
| Principal investigator 1 | PFIZER INC. | $7,678.26 | 02/19/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228837260 |
| Principal investigator 1 | Eli Lilly and Company | $1,088.18 | 02/17/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881882 |
| Principal investigator 1 | PFIZER INC. | $47,497.80 | 02/14/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228836591 |
| Principal investigator 1 | PFIZER INC. | $5,247.96 | 02/12/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228836232 |
| Principal investigator 1 | Eli Lilly and Company | $8,335.33 | 01/31/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882818 |
| Principal investigator 1 | Eli Lilly and Company | $3,616.53 | 01/30/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187881788 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $45,176.00 | 01/29/2025 | Non-covered Recipient Entity FLOURISH RESEARCH CHICAGO ANDERSONVILLE | A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C | No dispute reported | 06/30/2026 | 1185543628 |
| Principal investigator 1 | Eli Lilly and Company | $98,488.21 | 01/28/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187880447 |
| Principal investigator 1 | Eli Lilly and Company | $2,230.57 | 01/27/2025 | Non-covered Recipient Entity GREAT LAKES MEDICAL RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187882826 |
| Principal investigator 1 | PFIZER INC. | $5,154.80 | 01/25/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228863142 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,436.31 | 01/21/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials - West Wilson Avenue | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs | No dispute reported | 06/30/2026 | 1235997061 |
| Principal investigator 1 | Eli Lilly and Company | $22,112.00 | 01/21/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187880041 |
| Principal investigator 1 | Eli Lilly and Company | $147,157.30 | 01/17/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882814 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,608.00 | 01/15/2025 | Non-covered Recipient Entity FLOURISH RESEARCH CHICAGO ANDERSONVILLE | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185543624 |
| Principal investigator 1 | PFIZER INC. | $4,056.50 | 01/15/2025 | Non-covered Recipient Entity Great Lakes Clinical Trials LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228863163 |
| Principal investigator 1 | Eli Lilly and Company | $1,890.34 | 01/09/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881884 |
| Principal investigator 1 | Eli Lilly and Company | $17,154.61 | 01/08/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187879795 |
| Principal investigator 1 | Eli Lilly and Company | $173,511.00 | 01/07/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187880391 |
| Principal investigator 1 | Eli Lilly and Company | $314,231.00 | 01/07/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187881880 |
| Principal investigator 1 | Eli Lilly and Company | $900,848.26 | 01/07/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187881892 |
| Principal investigator 1 | Eli Lilly and Company | $302,707.19 | 01/07/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882822 |
| Principal investigator 1 | AstraZeneca UK Limited | $340,681.00 | 01/03/2025 | Non-covered Recipient Entity FLOURISH RESEARCH CHICAGO ANDERSONVILLE | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185543616 |
| Principal investigator 1 | Amgen Inc. | $1,993,198.69 | 01/02/2025 | Non-covered Recipient Entity GREAT LAKES CLINICAL TRIALS LLC | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246641947 |